Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Equillium’s latest SEC disclosures can feel like parsing an entire immunology textbook. Clinical trial updates, milestone payments and patent discussions sprawl across hundreds of pages, while Form 4 insider trades often move the market before pivotal data drops. If you have ever searched “Equillium SEC filings explained simply” or asked, “Where do I find Equillium’s quarterly earnings report 10-Q filing?”, you know the challenge.
Stock Titan solves that problem with AI-powered summaries that translate dense language into clear takeaways. Our platform tracks every submission in real time—10-K annual reports, 10-Q quarterly earnings, 8-K material events, S-3 financings and the Equillium proxy statement executive compensation tables. Need to monitor “Equillium insider trading Form 4 transactions” or get an alert on “Equillium Form 4 insider transactions real-time”? We surface who bought, who sold, and why it matters. Interactive dashboards connect clinical spending from the 10-Q to risk factors in the 10-K, giving you an integrated view without wading through footnotes.
Whether you are comparing R&D burn rates, timing catalytic trial readouts or evaluating dilution risk, our coverage keeps you ahead. Quickly scan an “Equillium earnings report filing analysis”, dig into “Equillium annual report 10-K simplified”, or see “Equillium 8-K material events explained” moments after they hit EDGAR. With AI guidance for understanding Equillium SEC documents with AI, professional investors, analysts and healthcare specialists gain the clarity needed to act confidently.
Equillium, Inc. (EQ)11/25/2025, the officer sold 100 shares of common stock at $0.98 per share and another 7,998 shares at $0.95 per share. After these transactions, the officer beneficially owned 127,148 shares of Equillium common stock directly. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.
Equillium, Inc. filed a shelf registration on Form S-3 to offer up to $250,000,000 of securities (common stock, preferred stock, debt, and warrants) from time to time, with terms to be set by prospectus supplements. The filing also includes a dedicated sales agreement prospectus for an at-the-market offering of up to $75,000,000 of common stock through LifeSci Capital, included within the $250,000,000 shelf.
Under the ATM, LifeSci Capital will act as sales agent on a commercially reasonable efforts basis, and will receive up to 3.0% of gross proceeds as compensation. Proceeds to the company will be used for general corporate purposes, including research and development, working capital, and capital expenditures, as later specified in supplements.
Equillium’s common stock trades on Nasdaq as “EQ,” and the last reported sale price was $0.924 per share on November 12, 2025. Shares outstanding were 60,676,837 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Equillium, Inc. (EQ)$4.23 million$0 revenue$4.58 million
Cash and cash equivalents were $33.12 million$30.94 million~$30 million gross~$20 million~$0.9 million gross60,676,83760,893,283
The company terminated prior Biocon agreements and is focusing on EQ504through 2027.
Equillium, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into other SEC filings except as expressly specified by reference.
Equillium, Inc. filed a Form 8-K reporting a letter from independent auditor KPMG LLP dated
Equillium, Inc. reports an estimated public float of $93.7 million, calculated from 47,085,662 shares held by non-affiliates and a per‑share price of $1.99. The $1.99 price was the highest closing price on The Nasdaq Capital Market within 60 days of this prospectus supplement's filing, specifically on September 11, 2025. The public float figure follows the method in General Instruction I.B.6 of Form S-3 under the Securities Act of 1933.
The company notes this figure is specific to the current filing and that if it later becomes subject to the limitations in General Instruction I.B.6, it will file another supplement to update the ATM prospectus. No other financial results, transactions, or forward-looking statements are provided in this excerpt.
Equillium, Inc. filed an S-3 shelf registration to register common stock for resale by selling stockholders, including shares issuable upon exercise of pre-funded warrants sold in a recent private placement. The prospectus identifies multiple institutional holders (including Adage, ADAR1 Entities, Coastlands Capital and Janus) and shows specific share counts and warrants subject to beneficial ownership blockers that exclude certain exercisable shares from pre-offering ownership figures. The filing lists exhibits (e.g., merger agreement, charter documents, Registration Rights Agreement dated August 12, 2025 and pre-funded warrant form dated August 11, 2025) and incorporates prior SEC reports by reference. The total filing fee shown aggregates to $81,562.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
